IPO Ideas
Anthem Biosciences Limited IPO logo

Anthem Biosciences Limited IPO

BBMainboardBSE, NSEListed
Listed at
723.05
+26.85%

Anthem Biosciences Limited IPO is a Mainboard book building IPO. Price band is ₹570 per share. Minimum investment is ₹14,820. Lot size is 26 shares. Open from 14 Jul 2025 to 16 Jul 2025. Allotment on 17 Jul 2025. Listing on 21 Jul 2025 at BSE, NSE. Managed by Jm Financial Limited,Citigroup Global Markets India Private Limited,J.P. Morgan India Private Limited,Nomura Financial Advisory And Securities (India) Pvt Ltd. Registrar: Kfin Technologies Limited. Key details for GMP, subscription, price, allotment, and listing in one place.

Official documents: RHP and DRHP.

Anthem Biosciences Limited IPO overview

Anthem Biosciences Limited IPO Key figures

Price band, lot, minimum application, and issue window at a glance.

Price band
₹570
Lot size
26 shares / lot
Min investment
₹14,820
Issue open – close
14 Jul 2025 → 16 Jul 2025

Anthem Biosciences Limited IPO important dates

Issue Opens
14 Jul 2025
Issue Closes
16 Jul 2025
Allotment
17 Jul 2025
Listing
21 Jul 2025

Anthem Biosciences Limited IPO lot size

CategoryLotsSharesAmount
Retail (Min)12614,820
Retail (Max)133381,92,660
S-HNI (Min)143642,07,480
S-HNI (UPI)338584,89,060
S-HNI (Max)671,7429,92,940
B-HNI (Min)681,76810,07,760

About Anthem Biosciences Limited IPO

From the company / RHP narrative.

Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.

The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.

The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.

As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).

As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.

As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.

As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.

As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.

Competitive Strength


One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
Long-standing relationships with a large, diversified and loyal customer base.
Professional and experienced leadership team supported by a qualified scientific talent pool.
Anthem Biosciences Limited IPO FAQs
A quick overview of key terms, dates, and how to track this IPO.

Documents & links

Prospectus, draft filings, and company site open in a new tab.

Registrar

Details about the registrar of the issue.

Registrar Name
Kfin Technologies Limited
Phone
4067162222
Address
KFintech, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Gachibowli, Hyderabad, Telangana India - 500 032.

Issue details

Key details about the issue, including the face value, lot size, and minimum investment.

Issue Type
BB
Face Value
2
Lead Managers
Jm Financial Limited,Citigroup Global Markets India Private Limited,J.P. Morgan India Private Limited,Nomura Financial Advisory And Securities (India) Pvt Ltd
Min Quantity
26
Company Promoters
Ajay Bhardwaj,Ganesh Sambasivam,K Ravindra Ch,rappa,Ishaan Bhardwaj.
Phone
+91 080 6672 400
Address
Anthem Biosciences Ltd. No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099

Related articles

Research posts and updates that reference this company or theme.

Follow IPO & unlisted research in the app, available on iOS and Android.